International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib Data

news_bristol myers squibb blog image-515_
Bristol Myers Squibb (BMS) presented new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis. This data adds to the growing amount of evidence proving Deucravacitinib could be a new oral treatment option for moderate to severe plaque psoriasis. Deucravacitinib is currently under regulatory review in multiple regions, including the United States, Europe, and Japan. If approved, it would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved to treat any disease.
Bristol myers squibb logo small

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

Psoriasis in Older Patients: Key Considerations and Best Practices for Effective Management

Getting to Know IPC’s Board Member Lone Skov: What Inspired Me to Specialize in Psoriasis

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.